DF/HCC Pipelines in Oncology: Agios

Thursday, March 20 at 12:30pm to 2:00pm

Register for this event

Agios is dedicated to the development of metabolic inhibitors/therapeutic agents, such as AG-221 (IDH2 inhibitor), AG-120 (IDH1 inhibitor) AG-348 (pyruvate kinase R activator), as well as other candidate metabolic cancer targets.
 
Visiting from Agios will be Samuel Agresta, MD, MPH & TM/TR, Senior Director and Head of Clinical Development. Dr. Agresta will be meeting with investigators at MGH in the morning and DFCI in the afternoon. If you are interested in a small group or 1:1 meeting with Dr. Agresta, please write to Andrea Talis (MGH), or Deborah Goff (DFCI). 

Lunch will be provided at DFCI for the seminar

Share
Subscribe
Event Type

Clinical Research

Website

http://www.dfhcc.harvard.edu/member-r...

Event Contact Name

Deborah Goff

Event Contact Email

Deborah_Goff@dfci.harvard.edu

Recent Activity


NCI CCC